抗耐多药结核病新药的研究进展

中国防痨杂志 ›› 2012, Vol. 34 ›› Issue (5): 324-326.

抗耐多药结核病新药的研究进展

赵恒敏王卫华

430021湖北省武汉市商业职工医院门诊部（赵恒敏）；武汉市结核病防治所湖北省结核病防治临床技术指导中心（王卫华）

收稿日期:2011-12-08 出版日期:2012-05-10 发布日期:2012-05-03
通信作者: 王卫华 E-mail:drwang65@163.com

Research progress of new drugs for anti multi-drug resistance tuberculosis (MDR-TB)

ZHAO Heng-min, WANG Wei-hua

Received:2011-12-08 Online:2012-05-10 Published:2012-05-03
Contact: WANG Wei-hua E-mail:drwang65@163.com

摘要/Abstract

摘要： 耐多药结核病（multidrug-resistant tuberculosis, MDR-TB）是至少同时对两种抗结核药物——INH和RFP耐药的Mtb感染引起的疾病。据WHO报道2008年全球共有MDR-TB患者440 000例，肺结核患者中MDR-TB占5.3%；2009年仅仅11%患者被诊断发现、1%患者接受治疗。耐多药结核病在许多国家已成为重大的公共卫生问题和全球结核病有效控制的障碍。

赵恒敏王卫华. 抗耐多药结核病新药的研究进展[J]. 中国防痨杂志, 2012, 34(5): 324-326.

ZHAO Heng-min, WANG Wei-hua. Research progress of new drugs for anti multi-drug resistance tuberculosis (MDR-TB)[J]. Chinese Journal of Antituberculosis, 2012, 34(5): 324-326.

参考文献

［1］Falzon D, Jaramillo E,Schünemann HJ,et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J, 2011, 38(3):516-528.

［2］Chiang CY,Centis R,Migliori GB. Drug-resistant tuberculosis: past, present, future. Respirology, 2010, 15(3):413-432.

［3］The Lancet Infections Diseases.The worldwide epidemic of multidrug-resistant tuberculosis. Lancet Infect Dis, 2011, 11(5):333.

［4］World Health Organization (WHO). Medicines for tuberculosis［J/OL］.WHO Drug Information, 2006，20（4）：239-245. ［2011-05-05］.http://whqlibdoc.who.int/druginfo/20_4_2006.pdf.

［5］谭金哲，董景涛. 抗结核新药SQ109、PA-824、OPC-67683与R207910研究进展.中国抗生素杂志,2010,35(6):408-411.

［6］Nuermberger E,Rosenthal I,Tyagi S,et al.Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother, 2006, 50(8):2621-2625.

［7］高凌玉,周建琴,孙承航. 抗结核候选新药PA-824的研究进展.国外医药抗生素分册,2006,27(6):241-244.

［8］TB Alliance. TB alliance launchers first clinical trial of a novel tb drug regimen ［R/OL］(2010-11-08)［2011-05-05］.http://www.tballiance.org/newscenterr/view-brief.php?id=942.

［9］Andries K,Verhasselt P,Guillemont J,et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707):223-227.

［10］Lounis N,Gevers T,Van Den Berg J,et al.Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.Antimicrob Agents Chemother,2008,52(10):3568-3572.

［11］Lounis N,Veziris N,Chauffour A,et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother, 2006,50(11):3543-3547.

［12］Tibotec Pharmaceuticals Limited. Anti-bacterial activity, safety, and tolerability of TMC207 in patients with multi-drug resistant Mycobacterium tuberculosis (MDR-TB)［R/OL］. Bethesda （MD）:US National Library of Medicine. 2007［2010-05-05］. http://www.clinicaltrials.gov.ct.Show/NCT00449644?order=1.

［13］Diacon AH,Pym A,Grobusch M,et al.The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009,360(23):2397-2405.

［14］Churchyard GJ, Friedland G,Fielding K,et al. Opportunities afforded by new drugs for tuberculosis. Lancet Infect Dis, 2010, 10(6):368-369.

［15］Leibert E, Rom WN. New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther, 2010,8(7):801-813.

［16］朱友生.抗结核药物研究进展. 中国防痨杂志,2007,29(4): 348-350.

［17］黄海荣，于霞，姜广路，等. 利奈唑胺治疗耐多药结核病的初步评价.中国防痨杂志,2011,33(5): 275-279.

［18］唐神结, 肖和平.广泛耐药结核病的现状与对策. 中华医学杂志,2011，91（5）: 355-358.

［19］Amaral L, Boeree MJ,Gillespie SH,et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents, 2010, 35(6):524-526.

［20］Amaral L, Molnar J. Therapy of XDR-TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”. Recent Pat Antiinfect Drug Discov, 2010, 5(2):109-114.

［21］Viveiros M, Martins M, Couto I, et al. Molecular tools for rapid identification and novel effective therapy against MDR-TB/XDR-TB infections. Expert Rev Anti Infect Ther, 2010, 8(4):465-480.

［22］Amaral L,Martins M,Viveiros M. Phenothiazines as anti-multi-drug resistant tubercular agents. Infect Disord Drug Targets, 2007,7(3):257-265.

［23］TB Alliance. Since its founding in 2000,TB Alliance has built the largest, most diverse tuberculosis drug pipeline in history［R/OL］.［2010-05-05］.http://www.tballiance.org/new/portfolio.php.